Literature DB >> 19787150

Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?

A L Chagas1, L O O Kikuchi, C P M S Oliveira, D C P Vezozzo, E S Mello, A C Oliveira, L C Cella, P Herman, T Bachella, S H Caldwell, V A F Alves, F J Carrilho.   

Abstract

Non-alcoholic steatohepatitis (NASH) has been associated with hepatocellular carcinoma (HCC) often arising in histologically advanced disease when steatohepatitis is not active (cryptogenic cirrhosis). Our objective was to characterize patients with HCC and active, histologically defined steatohepatitis. Among 394 patients with HCC detected by ultrasound imaging over 8 years and staged by the Barcelona Clinic Liver Cancer (BCLC) criteria, we identified 7 cases (1.7%) with HCC occurring in the setting of active biopsy-proven NASH. All were negative for other liver diseases such as hepatitis C, hepatitis B, autoimmune hepatitis, Wilson disease, and hemochromatosis. The patients (4 males and 3 females, age 63 +/- 13 years) were either overweight (4) or obese (3); 57% were diabetic and 28.5% had dyslipidemia. Cirrhosis was present in 6 of 7 patients, but 1 patient had well-differentiated HCC in the setting of NASH without cirrhosis (fibrosis stage 1) based on repeated liver biopsies, the absence of portal hypertension by clinical and radiographic evaluations and by direct surgical inspection. Among the cirrhotic patients, 71.4% were clinically staged as Child A and 14.2% as Child B. Tumor size ranged from 1.0 to 5.2 cm and 5 of 7 patients were classified as early stage; 46% of all nodules were hyper-echoic and 57% were <3 cm. HCC was well differentiated in 1/6 and moderately differentiated in 5/6. Alpha-fetoprotein was <100 ng/mL in all patients. HCC in patients with active steatohepatitis is often multifocal, may precede clinically advanced disease and occurs without diagnostic levels of alpha-fetoprotein. Importantly, HCC may occur in NASH in the absence of cirrhosis. More aggressive screening of NASH patients may be warranted.

Entities:  

Mesh:

Year:  2009        PMID: 19787150     DOI: 10.1590/s0100-879x2009005000019

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  23 in total

1.  Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis.

Authors:  Fabiola Rabelo; Claudia P M S Oliveira; Joel Faintuch; Daniel F C Mazo; Vicencia M R Lima; Jose Tadeu Stefano; Hermes V Barbeiro; Francisco G Soriano; Venancio A Ferreira Alves; Flair J Carrilho
Journal:  Obes Surg       Date:  2010-07       Impact factor: 4.129

Review 2.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review.

Authors:  Yoshitaka Takuma; Kazuhiro Nouso
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

Review 3.  Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.

Authors:  Hiroyasu Sakai; Yohei Shirakami; Masahito Shimizu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways.

Authors:  Ryan B Perumpail; Andy Liu; Robert J Wong; Aijaz Ahmed; Stephen A Harrison
Journal:  World J Hepatol       Date:  2015-10-08

5.  Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD): a multicenter prospective study.

Authors:  Claudia P Oliveira; José Tadeu Stefano; Flair José Carrilho
Journal:  Hepatobiliary Surg Nutr       Date:  2017-10       Impact factor: 7.293

6.  Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatitic inflammatory non-proliferative subtype.

Authors:  Priscila B de Campos; Claudia P Oliveira; José T Stefano; Sebastião N Martins-Filho; Aline L Chagas; Paulo Herman; Luiz C D'Albuquerque; Mário R Alvares-da-Silva; Adhemar Longatto-Filho; Flair J Carrilho; Venancio A F Alves
Journal:  Histol Histopathol       Date:  2019-12-20       Impact factor: 2.303

Review 7.  Cryptogenic chronic hepatitis and its changing guise in adults.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

Review 8.  Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment.

Authors:  Howard P Monsour; Catherine T Frenette; Kathleen Wyne
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

Review 9.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

Review 10.  Primary hepatocellular carcinoma and metabolic syndrome: An update.

Authors:  Rubayat Rahman; Ghassan M Hammoud; Ashraf A Almashhrawi; Khulood T Ahmed; Jamal A Ibdah
Journal:  World J Gastrointest Oncol       Date:  2013-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.